Chronically high levels of circulating FFAs, in turn, exacerbate metabolic dysfunction, and pharmacological inhibition of lipolysis improves insulin sensitivity and glucose tolerance in subjects with obesity and/or type 2 diabetes and in mouse models of diet-induced obesity [33,34,35,36]. The gene discussed is INS; the disease is obesity disorder.